

Synthesis of the Precursor of Anti-Inflammatory Agents by Cross-Coupling Using Electrogenerated Highly Reactive Zinc

Aishah A. Jalil, Nobuhito Kurono, Masao Tokuda*

Division of Molecular Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo 060-8628, Japan
Fax +81(11)7066598; E-mail: tokuda@org-mc.eng.hokudai.ac.jp

Received 19 August 2002; revised 25 September 2002

Abstract: Highly reactive zinc metal was readily prepared by electrolysis of a DMF solution containing naphthalene and a supporting electrolyte in a one-compartment cell fitted with a platinum cathode and a zinc anode. This reactive zinc was used for efficient transformation of ethyl 2-bromoacrylate into the corresponding organozinc compound, which was reacted with various aryl iodides in the presence of palladium catalyst to give the corresponding cross-coupling products, ethyl 2-arylpropenoates, in high yields. These cross-coupling reactions were successfully applied to a synthesis of the precursors of non-steroidal anti-inflammatory agents such as ibuprofen, naproxen, ketoprofen, loxoprofen, indoprofen, suprofen, flurbiprofen, and cicloprofen.

Key words: anti-inflammatory agents, cross-coupling, reactive zinc, organometallic reagents, electrolysis


2-Arylpropanoic acids are well-known as the lead structure of non-steroidal anti-inflammatory agents represented by ibuprofen.¹ Many synthetic strategies have been developed for the preparation of these acids, especially for their derivatives: e.g. methylation of arylacetic acids,² cyanation of 1-aryl-1-haloethanes,³ introduction of aryl group into the α -position of propanoic acids,⁴ rearrangement of propiophenones or their derivatives,⁵ and others.⁶ However, most of these synthetic approaches give *racemic* 2-arylpropanoic acids, whereas anti-inflammatory active compounds are (*S*)-2-arylpropanoic acids. Most useful method for the synthesis of (*S*)-2-arylpropanoic acids would be the preparation of 2-arylpropenoic acids followed by enantioselective hydrogenation with Ru-(*S*)-BINAP catalyst.⁷ Therefore, our attention has been directed to an efficient preparation of 2-arylpropenoic acids or their derivatives.

We have already reported the preparation of 2-phenylpropenoic acid by electrochemical carboxylation of α -bromostyrene and its application to efficient synthesis of the precursor of ibuprofen, 2-(*p*-isobutylphenyl)propenoic acid.⁸ On the other hand, we recently examined the preparation of 2-arylpropenoic acid esters by using a cross-coupling reaction of ethyl 2-bromoacrylate with aryl halides. We developed very efficient method for the synthesis of ethyl 2-arylpropenoates by cross-coupling reaction of organozinc compound, derived from ethyl 2-bromoacrylate and electrogenerated highly reactive zinc,

with aryl iodides⁹ or bromides¹⁰ in the presence of a Pd(II) catalyst. In this paper we report a successful application of these cross-coupling reactions to an efficient synthesis of the precursor of various anti-inflammatory agents such as ibuprofen, naproxen, ketoprofen, loxoprofen, indoprofen, suprofen, flurbiprofen, and cicloprofen. Similar cross-coupling of α -stannyl acrylate with aryl iodides or triflates has been reported to give methyl 2-arylpropenoates in moderate yields and was found to be applicable to the synthesis of the precursor of naproxen in 71% yield.¹¹

We have earlier reported a new method for the preparation of reactive zinc (EGZn) by electrolysis (Scheme 1) and its use in facile isoprenylation¹² and allylation^{13,14} of aldehydes and ketones. We have also reported a facile preparation of organozinc compounds from functionalized alkyl iodides by using EGZn and their cross-couplings with aryl halides.¹⁵ However, organozinc bromides were rarely obtained or were only obtained in very low yields from the corresponding organic bromides, even if the reactive EGZn was used. Therefore, we developed a new electrochemical method for preparation of more highly reactive zinc (EGZn/Naph) by using naphthalene as a mediator.⁹

Highly reactive zinc was readily prepared by constant-current electrolysis of a DMF solution containing 0.1 M Et₄NClO₄ in the presence of naphthalene. Electrolysis was carried out at -10 °C in a one-compartment cell fitted with a platinum plate cathode and a zinc plate anode.⁹ In this electrolysis, a one-electron reduction of naphthalene molecule gives naphthalene radical anions, which reduce zinc ions, generated by anodic dissolution of the zinc metal, to give zero-valent highly reactive zinc (EGZn/Naph) (Scheme 1).



Scheme 1

The reaction of EGZn/Naph with ethyl 2-bromoacrylate (**1**) gave efficiently the corresponding organozinc bromide **2** and subsequent cross-coupling reaction with various aryl iodides **3** in the presence of palladium catalyst proceeded efficiently to give ethyl 2-arylpropenoates **4** in

almost quantitative yields (Scheme 2).⁹ All of the steps involving the electrochemical preparation of highly reactive EGZn/Naph, the transformation of **1** to the corresponding organozinc **2**, and the cross-coupling reaction of **2** with aryl iodides **3** were carried out in a one-pot.

We applied these efficient cross-coupling reactions to a synthesis of the precursor of anti-inflammatory agents. Cross-coupling reaction of organozinc bromide **2** with 4-isobutyl iodobenzene (**3a**) gave the precursor of ibuprofen (**4a**) in 93% yield. Similar one-pot reactions of **2** with aryl iodides **3b–h** afforded the precursor of ketoprofen (**4b**) cicloprofen (**4c**), loxoprofen (**4d**), indoprofen (**4e**), naproxen (**4f**), suprofen (**4g**), and flurbiprofen (**4h**) in high yields, respectively. Results are summarized in Table 1.

IR spectra were recorded on a Jasco IR-810 IR spectrometer. ¹H NMR spectra were recorded on a Jeol JNM-EX270 FT NMR spectrometer operated at 270 MHz (solvent CDCl₃). Proton-decoupled ¹³C NMR spectra were recorded at 67.5 MHz on a Jeol JNM-EX270 spectrometer. ¹H and ¹³C chemical shifts are reported in ppm (δ) using SiMe₄ as an internal standard. High and low resolution mass spectra were determined with a Jeol JMS-AX500 or Jeol JMS-SX102A spectrometer. TLC and column chromatography were carried out on Merck silica gel (60 PF-254). Commercially available anhyd DMF packed under N₂ (Kanto Chemical) was used without further purification. Et₃NClO₄ was prepared according to the previously reported method.¹⁵ Zinc plate is commercially available in more than 99.9% purities, and they were washed with 2 N HCl before electrolysis. Commercially available naphthalene (Junsei Chemical, 99%) was used after recrystallization from MeOH. Iodobenzene is commercially available and was purified by distillation prior to use.

Ethyl 2-bromoacrylate,¹⁶ and 1-iodo-4-isobutylbenzene (**3a**)¹⁷ were prepared according to the procedure reported in the literature. 3-Iodobenzophenone (**3b**), 2-iodofluorene (**3c**), 2-iodo-6-methoxynaphthalene (**3f**), 2-(4-iodobenzoyl)thiophene (**3g**),¹⁸ 2-fluoro-4-iodobiphenyl (**3h**) were prepared by iodination of the corresponding aryl bromides according to the literature.¹⁹ 2-(4-Iodobenzyl)cyclopentanone (**3d**) and 2-(4-iodophenyl)-2,3-dihydroisindol-1-one (**3e**) were prepared by the following procedures described below.

Ethyl 2-Bromoacrylate (**1**)¹⁶

Yield: 82%; colorless oil; bp 80 °C/69 mmHg.

IR (neat): 1725, 1605, 1259, 1102 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 6.96 (d, 1 H, *J* = 1.7 Hz), 6.27 (d, 1 H, *J* = 1.7 Hz), 4.29 (q, 2 H, *J* = 7.3 Hz), 1.34 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 161.72, 130.26, 121.47, 62.57, 13.93.

EIMS: *m/z* (%) = 180 (18), 178 (18), 150 (19), 133 (40), 105 (49), 99 (65), 45 (100).

HRMS: *m/z* calcd for C₅H₇BrO₂: 177.9629. Found: 177.9622.

1-Iodo-4-isobutylbenzene (**3a**)¹⁹


Yield: 61%; bp 120–122 °C/16 mmHg.

IR (neat): 1484, 1465, 1401, 1384, 1007 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.58 (dd, 2 H, *J* = 2.0, 6.6 Hz), 6.90 (dd, 2 H, *J* = 2.0, 6.6 Hz), 2.41 (d, 2 H, *J* = 7.26 Hz), 1.82 (m, 1 H), 0.88 (d, 6 H, *J* = 6.6 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 141.22, 137.07, 131.20, 90.66, 44.84, 30.08, 22.25.

EIMS: *m/z* (%) = 260 (73), 232 (68), 217 (100), 203 (18), 128 (17), 89 (27), 77 (14).



Scheme 2

HRMS: *m/z* calcd for C₁₀H₁₃I: 260.0062. Found: 260.0066.

3-Iodobenzophenone (**3b**)²⁰

IR (neat): 3058, 1663, 1447, 1270, 715, 658 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 8.13 (t, 1 H, *J* = 1.7 Hz), 7.92 (dd, 1 H, *J* = 1.0, 7.9 Hz), 7.75 (m, 3 H), 7.60 (d, 2 H, *J* = 7.3 Hz), 7.53 (m, 1 H), 7.23 (t, 1 H, *J* = 7.9 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 194.95, 141.06, 139.41, 138.51, 136.78, 132.76, 129.94, 129.88, 129.06, 128.37, 93.99.

EIMS: *m/z* (%) = 308 (69), 231 (23), 203 (10), 181 (8), 105 (100), 77 (39).

HRMS: *m/z* calcd for C₁₃H₉IO: 307.9698. Found: 307.9699.

2-Iodofluorene (**3c**)²¹

Yield: 53%; light yellow crystals; mp 123–125 °C (Lit.²¹ mp 124–126 °C).

IR (nujol): 3130, 1465, 1377, 821, 762, 729 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.89 (s, 1 H), 7.76 (d, 1 H, *J* = 7.9 Hz), 7.70 (d, 1 H, *J* = 7.9 Hz), 7.53 (d, 2 H, *J* = 7.9 Hz), 7.36 (m, 2 H), 3.87 (s, 2 H).

¹³C NMR (67.5 MHz, CDCl₃): δ = 145.34, 142.55, 141.17, 140.63, 135.60, 134.02, 127.21, 126.83, 124.91, 121.38, 119.91, 91.81, 36.52.

EIMS: *m/z* (%) = 292 (67), 165 (100), 83 (12).

















HRMS: *m/z* calcd for C₁₃H₉I: 291.9749. Found: 291.9749.

2-(4-Iodobenzyl)cyclopentanone (**3d**)

To a mixture of NaH (2.0 g, 26 mmol) and anhyd DMF (170 mL) in a 200 mL side-arm flask fitted with a reflux condenser and a N₂-inlet system, was added methyl cyclopentanone-2-carboxylate (6.2 mL, 50 mmol) via syringe and the mixture was stirred for 3 h. A DMF (20 mL) solution of 4-bromobenzyl chloride (12.5 g, 26 mmol) was added and the mixture was stirred for 4 d at r.t. The mixture was extracted with Et₂O (3 × 100 mL), and the Et₂O layer was washed with brine (4 × 100 mL), and dried (MgSO₄). Evaporation of the solvent gave methyl 1-(4-bromobenzyl)-2-oxocyclopentanecarboxylate as a yellow oil, which was used directly in the following reaction. A mixture of the crude product and 48% HBr (25 mL) in a 100 mL flask fitted with a reflux condenser and N₂-inlet system was refluxed for 22 h. The mixture was cooled and poured into ice-water and extracted with Et₂O. The combined organic solutions were washed with sat. aq Na₂CO₃ (2 × 100 mL), brine (100 mL) and dried (MgSO₄). Evaporation of the solvent gave the crude product 2-(4-bromobenzyl)cyclopentanone in 82% yield. Iodination of the product according to the literature¹⁹ gave **3d** as a crystalline solid in 64% yield; mp 83–84 °C.

IR (neat): 1721, 1460, 1378, 1154, 854 cm⁻¹.

Table 1 Synthesis of the Precursors of Anti-Inflammatory Agents^a

Entry	Aryl Iodide 3	Product 4	Yield (%) ^b
1	 3a	 4a	93
2	 3b	 4b	92
3	 3c	 4c	87
4	 3d	 4d	96
5	 3e	 4e	94
6	 3f	 4f	95
7	 3g	 4g	72
8	 3h	 4h	84

^a Organozinc bromide **2**, prepared from ethyl 2-bromoacrylate (**1**) (3 mmol) and EGZn/Naph (6 mmol) in DMF was reacted at 70 °C for 3 h with aryl iodides **3** (2 mmol) in the presence of 5 mol% of Pd[P(*o*-Tol)₃]₂Cl₂.

^b Isolated yields based on aryl iodides.

¹H NMR (270 MHz, CDCl₃): δ = 7.60 (dd, 2 H, *J* = 2.0, 8.3 Hz), 6.92 (dd, 2 H, *J* = 2.0, 8.3 Hz), 3.07 (d, 1 H, *J* = 13.2 Hz), 2.55–2.47 (m, 1 H), 2.40–2.25 (m, 2 H), 2.16–1.91 (m, 4 H), 1.82–1.61 (m, 1 H).

¹³C NMR (67.5 MHz, CDCl₃): δ = 219.71, 139.59, 137.43, 131.00, 91.30, 50.73, 38.10, 35.01, 29.00, 20.49.

EIMS: *m/z* (%) = 300 (100), 217 (80), 204 (14), 145 (9), 116 (11), 90 (14).

HRMS: *m/z* calcd for C₁₂H₁₃IO: 300.0011. Found: 300.0009.

Anal. Calcd for C₁₂H₁₃IO: C, 48.02; H, 4.37; I, 42.28. Found: C, 48.21; H, 4.57; I, 42.32.

2-(4-Iodophenyl)-2,3-dihydroisindol-1-one (**3e**)

To a mixture of *o*-formylphthalic acid (3.76 g, 25 mmol) and anhyd DMF (150 mL) in a 300 mL three-necked flask, were added MeI (15.6 g, 250 mmol) and NaHCO₃ (8.4 g, 100 mmol) and stirred for 66 h at r.t. The mixture was extracted with EtOAc (3 × 100 mL) and washed with H₂O (3 × 100 mL), brine (100 mL), and dried (MgSO₄). Evaporation of the solvent gave a colorless oil, which was used in the following reaction. A mixture of the crude product, 4-iodoaniline (7.0 g, 32 mmol), AcOH (1.4 mL), and triacetoxo boro-

hydride (9.8 g, 46 mmol) in anhyd CH_2Cl_2 (250 mL) was stirred for 47 h at r.t. The mixture was extracted with CH_2Cl_2 (2×100 mL), and the combined organic layers were washed with aq 2 N NaOH (100 mL), H_2O (2×100 mL), brine, and dried (MgSO_4). Evaporation of the solvent gave a crystalline solid, which was filtered to give **3e** in 83% yield; mp 200–203 °C.

IR (neat): 1686, 1465, 1377, 826, 731 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.93$ (d, 1 H, $J = 7.3$ Hz), 7.72–7.50 (m, 7 H), 4.84 (s, 2 H).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 167.51, 139.80, 139.28, 138.02, 132.90, 132.33, 128.50, 124.19, 122.64, 120.88, 87.85, 50.41$.

EIMS: m/z (%) = 335 (100), 307 (15), 208 (7), 179 (7), 104 (10), 90 (12), 76 (16).

HRMS: m/z calcd for $\text{C}_{14}\text{H}_{10}\text{INO}$: 334.9807. Found: 334.9798.

Anal. Calcd for $\text{C}_{14}\text{H}_{10}\text{INO}$: C, 50.17; H, 3.01; N, 4.18; I, 37.87. Found: C, 49.91; H, 3.10; N, 4.05; I, 38.16.

2-Iodo-6-methoxynaphthalene (**3f**)¹⁹

Yield: 38%; mp 145–146 °C (Lit.¹⁹ mp 146–147 °C).

^1H NMR (270 MHz, CDCl_3): $\delta = 8.14$ (s, 1 H), 7.68–7.46 (m, 3 H), 7.25–7.07 (m, 2 H), 3.92 (s, 3 H).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 157.93, 136.19, 134.68, 133.30, 130.55, 128.34, 128.30, 119.52, 105.63, 88.05, 55.28$.

EIMS: m/z (%) = 284 (100), 269 (18), 236 (56), 223 (13), 193 (27), 114 (44).

HRMS: m/z calcd for $\text{C}_{11}\text{H}_9\text{OI}$: 283.9698. Found: 283.9688.

2-(4-Iodobenzoyl)thiophene (**3g**)²²

Yield: 60%; mp 107–108 °C (Lit.²² mp 106.5 °C).

IR (nujol): 1625, 1460, 1377, 849 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.87$ (dd, 2 H, $J = 2.0, 6.6$ Hz), 7.75 (dd, 1 H, $J = 1.0, 4.6$ Hz), 7.62 (dd, 1 H, $J = 1.0, 3.6$ Hz), 7.59 (dd, 2 H, $J = 2.0, 6.6$ Hz), 7.17 (dd, 1 H, $J = 3.6, 4.6$ Hz).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 187.28, 143.11, 137.68, 137.38, 134.79, 134.59, 130.60, 128.07, 99.75$.

EIMS: m/z (%) = 314 (82), 231 (25), 203 (14), 187 (22), 111 (100), 76 (30).

HRMS: m/z calcd for $\text{C}_{11}\text{H}_7\text{IOS}$: 313.9263. Found: 313.9263.

2-Fluoro-4-iodobiphenyl (**3h**)

Yield: 40%.

IR (neat): 1205, 1158, 859, 764, 697 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.27$ –7.58 (m, 6 H), 7.19–7.13 (t, 2 H, $J = 8.3$ Hz).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 160.97, 133.53, 131.81, 128.66, 128.45, 127.92, 125.45, 125.07, 92.08$.

EIMS: m/z (%) = 298 (100), 170 (97), 151 (20), 144 (7), 99 (5), 85 (23), 75 (10), 51 (8).

HRMS: m/z calcd for $\text{C}_{12}\text{H}_8\text{FI}$: 297.9655. Found: 297.9654.

Electrogenerated Highly Reactive Zinc (EGZn/Naph)

A normal one-compartment cell equipped with a magnetic stirrer and a serum cap was used. Electrogenerated highly reactive zinc (EGZn/Naph) (6 mmol) was prepared by the electrolysis of a DMF solution (10 mL) containing 0.1 M Et_4NClO_4 (230 mg) and naphthalene (12 mmol) in a one-compartment cell fitted with a platinum plate cathode (2×2 cm^2) and a zinc plate anode (2×2 cm^2). Electrolysis was carried out at -10 °C at a constant current of 60 mA/ cm^2 under N_2 . The quantity of electricity passed was 0.012 Faradays, which corresponded to 2 Faradays per mol of zinc. The amount of

EGZn/Naph was calculated from the weight of dissolved zinc anode. A solution containing EGZn/Naph was directly used for the preparation of organozinc compounds after the zinc anode was removed from the electrolysis cell.

Cross-Coupling Reaction Using EGZn/Naph; General Procedure

To the DMF solution containing EGZn/Naph was added ethyl 2-bromoacrylate (**1**; 537 mg, 3 mmol) and the mixture was stirred at -20 °C under N_2 for 1 h. The appropriate aryl iodide **3** (2 mmol) and $\text{Pd}[\text{o-Tol}]_2\text{Cl}_2$ (0.11 mmol) were added, and the reaction mixture was stirred at 70 °C for 3 h. The resulting mixture was quenched with aq HCl solution and filtered. The filtrate was extracted with Et_2O (3×50 mL) and the combined organic layers were washed with H_2O (3×100 mL), sat. aq $\text{Na}_2\text{S}_2\text{O}_3$ solution (100 mL) and brine (100 mL), and dried (MgSO_4). After evaporation of Et_2O , the crude product was purified by column chromatography on silica gel with EtOAc–hexane to give the ethyl 2-arylpropenoate **4**.

Ethyl 2-(4-Isobutylphenyl)propenoate (**4a**)

Colorless oil.

IR (neat): 1720, 1615, 1512, 1466, 1367, 1199, 1181, 1089, 850, 806 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.34$ (d, 2 H, $J = 8.3$ Hz), 7.13 (d, 2 H, $J = 8.3$ Hz), 6.28 (d, 1 H, $J = 1.3$ Hz), 5.87 (d, 1 H, $J = 1.3$ Hz), 4.29 (q, 2 H, $J = 7.3$ Hz), 2.48 (d, 2 H, $J = 6.9$ Hz), 1.87 (m, 1 H), 1.33 (t, 3 H, $J = 7.3$ Hz), 0.91 (d, 6 H, $J = 6.9$ Hz).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 163.99, 142.41, 141.37, 130.91, 128.75, 125.45, 118.98, 60.90, 44.94, 30.01, 22.28, 13.95$.

EIMS: m/z (%) = 232 (63), 189 (100), 161 (16), 145 (15), 115 (28).

HRMS: m/z calcd for $\text{C}_{15}\text{H}_{20}\text{O}_2$: 232.1463. Found: 232.1472.

Anal. Calcd for $\text{C}_{15}\text{H}_{20}\text{O}_2$: C, 77.55; H, 8.68. Found: C, 77.68; H, 8.83.

Ethyl 2-(3-Benzoylphenyl)propenoate (**4b**)

IR (neat): 1720, 1663, 1618, 1448, 1200, 1026, 710 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.86$ –7.76 (m, 3 H), 7.75–7.57 (m, 3 H), 7.52–7.45 (m, 3 H), 6.43 (d, 1 H, $J = 1.0$ Hz), 5.96 (d, 1 H, $J = 1.0$ Hz), 4.30 (q, 2 H, $J = 7.3$ Hz), 1.33 (t, 3 H, $J = 7.3$ Hz).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 196.37, 166.31, 140.67, 137.45, 137.39, 136.96, 132.51, 132.33, 130.08, 129.92, 129.72, 128.30, 128.05, 127.71, 61.28, 14.18$.

EIMS: m/z (%) = 280 (45), 203 (69), 105 (100), 77 (52).

HRMS: m/z calcd for $\text{C}_{18}\text{H}_{16}\text{O}_3$: 280.1099. Found: 280.1094.

Anal. Calcd for $\text{C}_{18}\text{H}_{16}\text{O}_3$: C, 77.12; H, 5.75. Found: C, 76.78; H, 5.85.

Ethyl 2-(2-Fluorenyl)propenoate (**4c**)

IR (neat): 1720, 1610, 1457, 1401, 1209, 1025, 738 cm^{-1} .

^1H NMR (270 MHz, CDCl_3): $\delta = 7.80$ –7.62 (m, 2 H), 7.62 (d, 1 H, $J = 0.7$ Hz), 7.53 (d, 1 H, $J = 0.7$ Hz), 7.46–7.31 (m, 3 H), 6.35 (d, 1 H, $J = 1.3$ Hz), 5.95 (d, 1 H, $J = 1.3$ Hz), 4.32 (q, 2 H, $J = 7.3$ Hz), 3.92 (s, 2 H), 1.35 (t, 3 H, $J = 7.3$ Hz).

^{13}C NMR (67.5 MHz, CDCl_3): $\delta = 167.08, 143.52, 143.31, 143.02, 141.74, 141.22, 135.20, 127.04, 126.85, 126.76, 125.89, 125.01, 124.91, 120.02, 119.43, 61.12, 36.88, 14.22$.

EIMS: m/z (%) = 264 (85), 235 (22), 190 (100), 165 (16).

HRMS: m/z calcd for $\text{C}_{18}\text{H}_{16}\text{O}_2$: 264.1150. Found: 264.1162.

Anal. Calcd for $\text{C}_{18}\text{H}_{16}\text{O}_2$: C, 81.79; H, 6.10. Found: C, 81.84; H, 5.92.

Ethyl 2-[4-(2-Oxocyclopentylmethyl)phenyl]propenoate (4d)

IR (neat): 2962, 1741, 1719, 1615, 1514, 1455, 1405, 1199, 1183, 1023, 863, 702 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.35 (dd, 2 H, *J* = 2.0, 8.3 Hz), 7.15 (dd, 2 H, *J* = 2.0, 8.3 Hz), 6.31 (d, 1 H, *J* = 1.0 Hz), 5.87 (d, 1 H, *J* = 1.0 Hz), 4.29 (q, 2 H, *J* = 7.3 Hz), 3.16 (dd, 1 H, *J* = 4.0, 13.5 Hz), 2.54 (dd, 1 H, *J* = 9.6, 13.5 Hz), 2.35 (m, 2 H), 2.05 (m, 4 H), 1.73 (m, 1 H), 1.34 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 219.68, 166.52, 140.90, 139.82, 134.32, 128.34, 128.00, 125.59, 60.76, 50.57, 37.81, 34.95, 28.86, 20.24, 13.91.

EIMS: *m/z* (%) = 272 (83), 198 (46), 189 (100), 141 (26), 115 (48), 91 (25).

HRMS: *m/z* calcd for C₁₇H₂₀O₃: 272.1412. Found: 272.1418.

Anal. Calcd for C₁₇H₂₀O₃: C, 74.97; H, 7.40. Found: C, 74.66; H, 7.43.

Ethyl 2-[4-(1-Oxo-1,3-dihydroisoindol-2-yl)phenyl]propenoate (4e)

Mp 110–111 °C.

IR (nujol): 2854, 1721, 1687, 1467, 1154, 735 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.95–7.87 (m, 3 H), 7.61–7.58 (m, 1 H), 7.54–7.49 (m, 4 H), 6.34 (d, 1 H, *J* = 1.0 Hz), 5.92 (d, 1 H, *J* = 1.0 Hz), 4.88 (s, 2 H), 4.31 (q, 2 H, *J* = 7.3 Hz), 1.35 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 167.49, 166.76, 140.70, 140.02, 139.35, 133.08, 132.65, 132.15, 129.04, 128.39, 126.00, 124.13, 122.61, 118.74, 61.12, 50.59, 14.20.

EIMS: *m/z* (%) = 307 (100), 234 (64), 209 (9), 103 (8), 90 (6), 77 (6).

HRMS: *m/z* calcd for C₁₉H₁₇NO₃: 307.1208. Found: 307.1210.

Anal. Calcd for C₁₉H₁₇NO₃: C, 74.25; H, 5.58; N, 4.56. Found: C, 74.09; H, 5.74; N, 4.27.

Ethyl 2-(6-Methoxynaphthalen-2-yl)propenoate (4f)

IR (neat): 1711, 1605, 1459, 1262, 1196, 1030, 859, 829, 813 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.84 (s, 1 H), 7.73 (t, 2 H, *J* = 8.3 Hz), 7.50 (dd, 1 H, *J* = 2.0, 8.3 Hz), 7.14 (d, 2 H, *J* = 8.3 Hz), 6.38 (d, 1 H, *J* = 1.0 Hz), 5.98 (d, 1 H, *J* = 1.0 Hz), 4.32 (q, 2 H, *J* = 7.3 Hz), 3.91 (s, 3 H), 1.35 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 166.72, 157.81, 141.22, 134.00, 131.70, 129.52, 128.27, 126.99, 126.34, 126.16, 125.61, 118.78, 105.27, 60.83, 54.92, 13.95.

EIMS: *m/z* (%) = 256 (100), 228 (14), 183 (71), 168 (15), 139 (19).

HRMS: *m/z* calcd for C₁₆H₁₆O₃: 256.1099. Found: 256.1097.

Anal. Calcd for C₁₆H₁₆O₃: C, 74.98; H, 6.29. Found: C, 75.24; H, 6.39.

Ethyl 2-[4-(2-Thiophenecarbonyl)phenyl]propenoate (4g)

IR (neat): 1720, 1636, 1414, 1294, 1198, 1086, 1019, 845, 722 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.87 (dd, 2 H, *J* = 2.0, 6.6 Hz), 7.74 (dd, 1 H, *J* = 1.0, 5.0 Hz), 7.68 (dd, 1 H, *J* = 1.0, 4.0 Hz), 7.56 (dd, 2 H, *J* = 2.0, 6.6 Hz), 7.18 (dd, 1 H, *J* = 4.0, 5.0 Hz), 6.47 (d, 1 H, *J* = 1.0 Hz), 6.00 (d, 1 H, *J* = 1.0 Hz), 4.32 (q, 2 H, *J* = 7.3 Hz), 1.35 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 187.47, 166.02, 143.32, 140.47, 137.36, 134.72, 134.18, 128.84, 128.25, 127.94, 127.89, 61.19, 14.04.

EIMS: *m/z* (%) = 286 (72), 213 (29), 203 (33), 111 (100).

HRMS: *m/z* calcd for C₁₆H₁₄O₃S: 286.0663. Found: 286.0670.

Anal. Calcd for C₁₆H₁₄O₃S: C, 67.11; H, 4.93; S, 11.20. Found: C, 67.17; H, 4.99; S, 10.89.

Ethyl 2-[4-(2-Fluoro)biphenyl]propenoate (4h)

IR (neat): 1721, 1616, 1486, 1413, 1220, 1171, 835, 769, 698 cm⁻¹.

¹H NMR (270 MHz, CDCl₃): δ = 7.58–7.55 (m, 2 H), 7.48–7.37 (m, 5 H), 7.31–7.27 (m, 1 H), 6.41 (s, 1 H), 5.98 (s, 1 H), 4.33 (q, 2 H, *J* = 7.3 Hz), 1.36 (t, 3 H, *J* = 7.3 Hz).

¹³C NMR (67.5 MHz, CDCl₃): δ = 166.33, 161.19, 140.18, 135.45, 130.37, 129.06, 129.02, 128.57, 127.30, 124.40, 116.37, 116.01, 61.39, 14.27.

EIMS: *m/z* (%) = 270 (100), 197 (76).

HRMS: *m/z* calcd for C₁₇H₁₅FO₂: 270.1056. Found: 270.1054.

Anal. Calcd for C₁₇H₁₅FO₂: C, 75.54; H, 5.59; F, 7.03. Found: C, 75.71; H, 5.35; F, 6.68.

Acknowledgment

We thank the Japanese Ministry of Education, Science, Sports and Culture for financial support under a Grant-in-Aid for Scientific Research (B) (No. 11450342).

References

- (1) Rieu, J. P.; Boucherle, A.; Cousse, H.; Mouzin, G. *Tetrahedron* **1986**, *42*, 4095.
- (2) (a) Kenyon, W. G.; Kaiser, E. M.; Hauser, Ch. R. *J. Org. Chem.* **1965**, *30*, 2937. (b) Hicks, T. A.; Smith, C. E.; Williamson, W. R. N.; Day, E. H. *J. Med. Chem.* **1979**, *22*, 1460. (c) Harrison, I. T.; Lewis, B.; Nelson, P.; Rooks, W.; Roszkowski, A.; Tomolonis, A.; Fried, J. H. *J. Med. Chem.* **1969**, *13*, 203. (d) Closse, A.; Haefliger, W.; Hauser, D.; Gubler, H. U.; Dewald, B.; Baggolini, M. *J. Med. Chem.* **1981**, *24*, 1465. (e) Tamura, Y.; Yoshimoto, Y.; Kunimoto, K.; Tada, S.; Matsumura, S.; Maruyama, M.; Shibata, Y.; Enomoto, H. *J. Med. Chem.* **1981**, *24*, 43. (f) Fadel, A. *Synlett* **1992**, 48.
- (3) (a) Kobler, H.; Schuster, K. M.; Simchen, G. *Liebigs Ann. Chem.* **1978**, 1946. (b) Foulkes, J. A.; Hutton, J. *Synth. Commun.* **1979**, *9*, 625. (c) Bakshi, S. P.; Turner, E. E. *J. Chem. Soc.* **1961**, 171.
- (4) (a) Lawrence, N. J.; Liddle, J.; Bushell, S. M.; Jackson, D. A. *J. Org. Chem.* **2002**, *67*, 457. (b) Arai, A.; Ohara, Y.; Lizumi, T.; Takakuwa, Y. *Tetrahedron Lett.* **1983**, *24*, 1531. (c) Pinhey, J. T.; Rowe, B. A. *Tetrahedron Lett.* **1980**, *21*, 965. (d) Sprague, P. W.; Heikes, J. E. *J. Med. Chem.* **1977**, *20*, 726. (e) Hino, K.; Nakamura, H.; Nagai, Y.; Uno, H.; Nishimura, H. *J. Med. Chem.* **1983**, *26*, 222.
- (5) (a) Higgins, S. D.; Thomas, C. B. *J. Chem. Soc., Perkin Trans. 1* **1982**, 235. (b) Fujii, K.; Nakao, K.; Yamauchi, T. *Synthesis* **1982**, 456. (c) Tamura, Y.; Shirouchi, Y.; Haruta, J. I. *Synthesis* **1984**, 231. (d) Fujii, K.; Nakao, K.; Yamauchi, T. *Synthesis* **1983**, 444. (e) Giordano, C.; Castaldi, G.; Casagrande, F.; Belli, A. *J. Chem. Soc., Perkin Trans. 1* **1982**, 2575. (f) Castaldi, G.; Belli, A.; Uggeri, F.; Giordano, C. *J. Org. Chem.* **1983**, *48*, 4658. (g) Goosen, A.; Cleland, C. W. *J. Chem. Soc., Chem. Commun.* **1982**, 1311. (h) Tsuchihashi, G.; Mitamura, S.; Kitajima, K.; Kobayashi, K. *Tetrahedron Lett.* **1982**, *23*, 5427. (i) Shioiri, T.; Kawai, N. *J. Org. Chem.* **1978**, *43*, 2936.
- (6) (a) Hamon, D. P. G.; M-Westropp, R. A.; Newton, J. L. *Tetrahedron Lett.* **1993**, *34*, 5333. (b) Hamon, D. P. G.; M-Westropp, R. A.; Newton, J. L. *Tetrahedron: Asymmetry* **1993**, *4*, 1435.

- (7) (a) Ohta, T.; Takaya, H.; Kitamura, M.; Nagai, K.; Noyori, R. *J. Org. Chem.* **1987**, *52*, 3176. (b) Ashby, M. T.; Halpern, J. *J. Am. Chem. Soc.* **1991**, *113*, 589. (c) Manimaran, T.; Wu, T.-C.; Klobucar, W. D.; Kolich, C. H.; Stahly, G. P. *Organometallics* **1993**, *12*, 1467. (d) Zhang, X.; Uemura, T.; Matsumura, K.; Sayo, N.; Kumobayashi, H.; Takaya, H. *Synlett* **1994**, 501. (e) Mashima, K.; Kusano, K.; Sato, N.; Matsumura, Y.; Nozaki, K.; Kumobayashi, H.; Sayo, N.; Hori, Y.; Ishizaki, T.; Akutagawa, S.; Takaya, H. *J. Org. Chem.* **1994**, *59*, 3064.
- (8) Kamekawa, H.; Senboku, H.; Tokuda, M. *Electrochimica Acta* **1997**, *42*, 2117.
- (9) Aishah, A. J.; Kurono, N.; Tokuda, M. *Synlett* **2001**, 1944.
- (10) Aishah, A. J.; Kurono, N.; Tokuda, M. *Tetrahedron* **2002**, *58*, 7477.
- (11) Levin, J. I. *Tetrahedron Lett.* **1993**, *34*, 6211.
- (12) Tokuda, M.; Mimura, N.; Karasawa, T.; Fujita, H.; Suginome, H. *Tetrahedron Lett.* **1993**, *47*, 7607.
- (13) Tokuda M., Kurono N., Mimura N.; *Chem. Lett.*; **1996**, 1091.
- (14) Tokuda, M. *Novel Trends in Electroorganic Synthesis*; Torii, S., Ed.; Kodansha Ltd.: Tokyo, **1995**, 241.
- (15) Kurono, N.; Sugita, K.; Takasugi, S.; Tokuda, M. *Tetrahedron* **1999**, *55*, 6097.
- (16) Rachon, J.; Goedken, V.; Walborsky, H. M. *J. Org. Chem.* **1989**, *54*, 1006.
- (17) Barluenga, J.; Campos, P. J.; Gonzalez, J. M.; Asensio, G. *J. Chem. Soc., Perkin Trans. 1* **1984**, 2623.
- (18) 2-(4-Bromobenzoyl)thiophene was prepared according to the reported procedure: McKean, D. R.; Parrinello, G.; Renaldo, A. F.; Stille, J. K. *J. Org. Chem.* **1987**, *52*, 422.
- (19) (a) Bando, T.; Namba, Y.; Shishido, K. *Tetrahedron: Asymmetry* **1997**, *8*, 2159. (b) DMF was used instead of HMPA
- (20) (a) Wagner, P. J.; Waite, C. I. *J. Phys. Chem.* **1995**, *99*, 7388. (b) Ebert, G. W.; Klein, W. R. *J. Org. Chem.* **1991**, *56*, 4744.
- (21) Minabe, M.; Suzuki, K. *Bull. Chem. Soc. Jpn.* **1972**, *45*, 3196.
- (22) Cho, W. S.; Kim, H. J.; Littler, B. J.; Millar, M. A.; Lee, C. H.; Lindsey, J. S. *J. Org. Chem.* **1999**, *64*, 7890.